{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:43:15Z","timestamp":1793122995092,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010886","name":"Nestl\u00e9 Health Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.obpill.2025.100222","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T06:17:17Z","timestamp":1761373037000},"page":"100222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Optimizing GLP-1 therapies for obesity and diabetes management"],"prefix":"10.1016","volume":"16","author":[{"given":"Jarvis C.","family":"Noronha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc F.","family":"Van Gaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2831-3618","authenticated-orcid":false,"given":"Ian J.","family":"Neeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Fitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas FH.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Chiavaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0826-5236","authenticated-orcid":false,"given":"Cyril WC.","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3270-5772","authenticated-orcid":false,"given":"John L.","family":"Sievenpiper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.obpill.2025.100222_bib1","author":"Pedersen"},{"issue":"11","key":"10.1016\/j.obpill.2025.100222_bib2","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.obpill.2025.100222_bib3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"11","key":"10.1016\/j.obpill.2025.100222_bib4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.obpill.2025.100222_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.obpill.2025.100222_bib6","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.obpill.2025.100222_bib7","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1111\/dom.15913","article-title":"Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: filling the gaps","volume":"26","author":"Dubin","year":"2024","journal-title":"Diabetes Obes Metabol"},{"issue":"Suppl 4","key":"10.1016\/j.obpill.2025.100222_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metabol"},{"issue":"5","key":"10.1016\/j.obpill.2025.100222_bib9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","article-title":"A systematic review of the effect of semaglutide on lean mass: insights from clinical trials","volume":"25","author":"Bikou","year":"2024","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.obpill.2025.100222_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/DMSO.S141235","article-title":"Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes","volume":"10","author":"Sikirica","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.obpill.2025.100222_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.r1606","article-title":"Side effects of GLP-1 receptor agonists","volume":"390","author":"Manne-Goehler","year":"2025","journal-title":"Br Med J"},{"issue":"8","key":"10.1016\/j.obpill.2025.100222_bib12","first-page":"860","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among Obese commercially insured adults without diabetes","volume":"30","author":"Gleason","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"issue":"14","key":"10.1016\/j.obpill.2025.100222_bib13","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.obpill.2025.100222_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","article-title":"Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial","volume":"22","author":"Sandsdal","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.obpill.2025.100222_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.obpill.2025.100222_bib16","article-title":"Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: a narrative review and discussion of research needs","volume":"11","author":"Christensen","year":"2024","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2025.100222_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodqual.2025.105507","article-title":"Characteristics and food consumption for current, previous, and potential consumers of GLP-1 s","volume":"129","author":"Dilley","year":"2025","journal-title":"Food Qual Prefer"},{"issue":"1","key":"10.1016\/j.obpill.2025.100222_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jama.2024.6586","article-title":"Is weight loss-induced muscle mass loss clinically relevant?","volume":"332","author":"Conte","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.obpill.2025.100222_bib19","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","article-title":"Sarcopenia","volume":"393","author":"Cruz-Jentoft","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.obpill.2025.100222_bib20","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s41999-019-00233-w","article-title":"Sarcopenia and health-related outcomes: an umbrella review of observational studies","volume":"10","author":"Veronese","year":"2019","journal-title":"Eur Geriatr Med"},{"issue":"1","key":"10.1016\/j.obpill.2025.100222_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.obpill.2025.100222_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.obpill.2025.100222_bib23","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.obpill.2025.100222_bib24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ajcn\/87.1.150","article-title":"Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the health, aging, and body composition (Health ABC) study","volume":"87","author":"Houston","year":"2008","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"10.1016\/j.obpill.2025.100222_bib25","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/oby.22493","article-title":"Weight cycling as a risk factor for low muscle mass and strength in a population of males and females with obesity","volume":"27","author":"Rossi","year":"2019","journal-title":"Obesity"},{"issue":"2","key":"10.1016\/j.obpill.2025.100222_bib26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/jcsm.12922","article-title":"Systematic review and meta-analysis of protein intake to support muscle mass and function in healthy adults","volume":"13","author":"Nunes","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.obpill.2025.100222_bib27","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3945\/ajcn.115.119339","article-title":"Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss: a randomized trial","volume":"103","author":"Longland","year":"2016","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"10.1016\/j.obpill.2025.100222_bib28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3945\/jn.113.185280","article-title":"Dietary protein distribution positively influences 24-h muscle protein synthesis in healthy adults","volume":"144","author":"Mamerow","year":"2014","journal-title":"J Nutr"},{"issue":"6","key":"10.1016\/j.obpill.2025.100222_bib29","doi-asserted-by":"crossref","first-page":"1339s","DOI":"10.3945\/ajcn.114.084061","article-title":"Protein and healthy aging","volume":"101","author":"Paddon-Jones","year":"2015","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.obpill.2025.100222_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.obpill.2025.100222_bib31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metabol"},{"issue":"5","key":"10.1016\/j.obpill.2025.100222_bib32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ijo.2013.149","article-title":"Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults","volume":"38","author":"Lean","year":"2014","journal-title":"Int J Obes"},{"key":"10.1016\/j.obpill.2025.100222_bib33","article-title":"Glucagon-like Peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.obpill.2025.100222_bib34","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/oby.24067","article-title":"Nutritional considerations with antiobesity medications","volume":"32","author":"Almandoz","year":"2024","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.obpill.2025.100222_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.obpill.2025.100222_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ijo.2013.83","article-title":"Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-Year matched cohort study","volume":"38","author":"Johansson","year":"2014","journal-title":"Int J Obes"},{"issue":"7","key":"10.1016\/j.obpill.2025.100222_bib37","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cgh.2013.11.031","article-title":"Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials","volume":"12","author":"Stokes","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.obpill.2025.100222_bib38","doi-asserted-by":"crossref","DOI":"10.1007\/s11154-025-09967-4","article-title":"New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?","author":"Ryan","year":"2025","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266736812500066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266736812500066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:56:17Z","timestamp":1773316577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266736812500066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"alternative-id":["S266736812500066X"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2025.100222","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing GLP-1 therapies for obesity and diabetes management","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2025.100222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100222"}}